JP2010534676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534676A5 JP2010534676A5 JP2010518369A JP2010518369A JP2010534676A5 JP 2010534676 A5 JP2010534676 A5 JP 2010534676A5 JP 2010518369 A JP2010518369 A JP 2010518369A JP 2010518369 A JP2010518369 A JP 2010518369A JP 2010534676 A5 JP2010534676 A5 JP 2010534676A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- post
- patient
- traumatic stress
- stress disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940126062 Compound A Drugs 0.000 claims 19
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 19
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 5
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 5
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 4
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 4
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 4
- 239000000674 adrenergic antagonist Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 claims 3
- 229950005868 nepicastat Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 5,7-difluoro-1,2,3,4-tetrahydronaphth-2-yl Chemical group 0.000 claims 2
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 108091006146 Channels Proteins 0.000 claims 2
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 2
- 102100037346 Substance-P receptor Human genes 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 2
- 230000001773 anti-convulsant effect Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 150000003943 catecholamines Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010029412 Nightmare Diseases 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 229960002430 atomoxetine Drugs 0.000 claims 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical group CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 229940049906 glutamate Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000007595 memory recall Effects 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93503607P | 2007-07-23 | 2007-07-23 | |
| PCT/US2008/070948 WO2009015248A1 (en) | 2007-07-23 | 2008-07-23 | Treatment of post-traumatic stress disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534676A JP2010534676A (ja) | 2010-11-11 |
| JP2010534676A5 true JP2010534676A5 (OSRAM) | 2011-08-18 |
Family
ID=40281815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518369A Pending JP2010534676A (ja) | 2007-07-23 | 2008-07-23 | 心的外傷後ストレス障害の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090054403A1 (OSRAM) |
| EP (1) | EP2182952A4 (OSRAM) |
| JP (1) | JP2010534676A (OSRAM) |
| CN (1) | CN101951912A (OSRAM) |
| AU (1) | AU2008279091A1 (OSRAM) |
| CA (1) | CA2707858A1 (OSRAM) |
| CO (1) | CO6260078A2 (OSRAM) |
| MX (1) | MX2010000937A (OSRAM) |
| NZ (1) | NZ583193A (OSRAM) |
| RU (1) | RU2458691C2 (OSRAM) |
| SG (1) | SG183069A1 (OSRAM) |
| WO (1) | WO2009015248A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2182803A4 (en) * | 2007-07-23 | 2010-09-01 | Synosia Therapeutics | (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER |
| SG10201705968RA (en) * | 2007-08-06 | 2017-08-30 | Biotie Therapies Inc | Methods for treating dependence |
| AU2016208412A1 (en) * | 2007-08-06 | 2016-08-18 | Biotie Therapies, Inc. | Methods for treating dependence |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| US11885816B2 (en) * | 2013-11-26 | 2024-01-30 | University Of North Texas Health Science Center At Forth Worth | Personalized medicine approach for treating cognitive loss |
| SG11201701995PA (en) | 2014-09-18 | 2017-04-27 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| RU2614697C1 (ru) * | 2016-04-12 | 2017-03-28 | Общество с ограниченной ответственностью "Нормофарм" | Нейропротекторное средство |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| CN110996987A (zh) * | 2017-05-30 | 2020-04-10 | 保罗·G·爱默生 | 用于调控应激障碍中激素级联的组合物和方法 |
| US11284934B2 (en) * | 2017-07-05 | 2022-03-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating sleep disorders in patients via renal neuromodulation |
| JP7167155B2 (ja) | 2017-12-04 | 2022-11-08 | ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ | ドーパミン－β－ヒドロキシラーゼ阻害剤 |
| AU2018383098B2 (en) | 2017-12-11 | 2024-12-12 | Tonix Pharma Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN109966281B (zh) * | 2019-04-11 | 2021-04-27 | 北京大学 | PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用 |
| EP4005566B1 (en) * | 2019-07-25 | 2024-10-30 | Tokyo University of Science Foundation | Disulfiram and related compounds for treating, preventing or improving anxiety disorders or symptoms, and depressive disorders or symptoms |
| AU2023400662A1 (en) * | 2022-11-30 | 2025-06-19 | Blinklab Ltd | Psychopharmacological system and method using eyelid tracking |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| WO2003022283A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| EP1336406A1 (en) * | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| CN1662231A (zh) * | 2002-04-24 | 2005-08-31 | 柏树生物科学公司 | 包括应激相关障碍在内的功能性躯体障碍的预防与治疗 |
| EP1734920A2 (en) * | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| MX2008000248A (es) * | 2005-07-06 | 2008-03-19 | Sepracor Inc | Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos. |
| AU2008229203B2 (en) * | 2007-03-16 | 2014-05-29 | Emory University | Methods and compositions for treatment of drug addiction |
| US20090054414A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Rufinamide for the Treatment of Post-Traumatic Stress Disorder |
-
2008
- 2008-07-23 SG SG2012054540A patent/SG183069A1/en unknown
- 2008-07-23 WO PCT/US2008/070948 patent/WO2009015248A1/en not_active Ceased
- 2008-07-23 CA CA2707858A patent/CA2707858A1/en not_active Abandoned
- 2008-07-23 US US12/178,513 patent/US20090054403A1/en not_active Abandoned
- 2008-07-23 EP EP08796518A patent/EP2182952A4/en not_active Withdrawn
- 2008-07-23 AU AU2008279091A patent/AU2008279091A1/en not_active Abandoned
- 2008-07-23 MX MX2010000937A patent/MX2010000937A/es not_active Application Discontinuation
- 2008-07-23 RU RU2010106014/15A patent/RU2458691C2/ru not_active IP Right Cessation
- 2008-07-23 NZ NZ583193A patent/NZ583193A/en not_active IP Right Cessation
- 2008-07-23 CN CN200880108123XA patent/CN101951912A/zh active Pending
- 2008-07-23 JP JP2010518369A patent/JP2010534676A/ja active Pending
-
2010
- 2010-02-19 CO CO10019664A patent/CO6260078A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010106014A (ru) | Лечение посттравматического стрессового расстройства | |
| RU2007103313A (ru) | Комбинация бупропина и другого состава для эффективной потери веса | |
| JP2013544850A5 (OSRAM) | ||
| JP2013537887A5 (OSRAM) | ||
| EP2029136A1 (en) | Treatment for depressive disorders | |
| JP2005539068A5 (OSRAM) | ||
| JP2005523334A5 (OSRAM) | ||
| JP2012036212A5 (OSRAM) | ||
| JP2007513052A (ja) | セロトニン再取り込み阻害剤およびアゴメラチンの併用。 | |
| KR101816953B1 (ko) | １-[２-(２,４-디메틸-페닐술파닐)페닐]-피페라진의 치료적 용도 | |
| JP2009542819A5 (OSRAM) | ||
| JP2022519541A (ja) | 不安関連障害を処置するための組成物および方法 | |
| JP5553955B2 (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| JP2007505156A5 (OSRAM) | ||
| AU2004238381A1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| US20110039926A1 (en) | Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| JP2009542820A5 (OSRAM) | ||
| Lam | The importance of early symptom relief in antidepressant treatment: focus on agomelatine | |
| Roller et al. | Disease state management: Depression and antidepressants | |
| Roller et al. | Depression and antidepressants: Pharmacists have a crucial role in supporting patients living with depression by providing advice and counselling about pharmacological treatments and recommending various strategies to assist these people to improve their quality of life | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| JP2009545573A (ja) | サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン／ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物 | |
| Ilario et al. | Neuroleptic malignant syndrome without hyperthermia induced by aripiprazole extended-release injection | |
| Hollander | C. 16.01 Anxiety spectrum disorders over life cycle |